Safety and Biodistribution Evaluation of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin, in RS1-Deficient Mice
Guojie Ye(Applied Genetic Technologies (United States)), Jeffrey D. Chulay(Research Triangle Park Foundation), Thomas J. Conlon(Adelson Foundation), Peter Sonnentag(Covance (United States)), David R. Knop(Applied Genetic Technologies (United States)), Kellie Howard(LabCorp (United States)), Kirsten Erger(University of Florida), Alok Sharma
Cited by 29
Related Papers
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
|Circulation Research|2006|400
Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism
|Journal of Virology|2000|392
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
|Proceedings of the National Academy of Sciences|2009|322